PerkinElmer Releases New Dried Blood Spot Based COVID-19 Serology Test
Excerpt from the Press Release:
“WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a dry blood spot (DBS) based test for SARS-CoV-2 IgG using its GSP®/DELFIA® platform, enabling processing of up to 5,000 samples per day. The finger-prick sample collection device allows for both decentralized sample collection and high-throughput testing. The product is being marketed as a CE-IVD test, and the Company plans to apply for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA).”
Click the button below to read the Press Release:
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?